Literature DB >> 28778876

Heparan Sulfate Glycosaminoglycans in Glioblastoma Promote Tumor Invasion.

Vy M Tran1, Anna Wade1, Andrew McKinney1, Katharine Chen1, Olle R Lindberg1, Jane R Engler1, Anders I Persson1,2,3, Joanna J Phillips4,2,5.   

Abstract

Glioblastoma (GBM) is the most common primary malignant brain tumor of adults and confers a poor prognosis due, in part, to diffuse invasion of tumor cells. Heparan sulfate (HS) glycosaminoglycans, present on the cell surface and in the extracellular matrix, regulate cell signaling pathways and cell-microenvironment interactions. In GBM, the expression of HS glycosaminoglycans and the enzymes that regulate their function are altered, but the actual HS content and structure are unknown. However, inhibition of HS glycosaminoglycan function is emerging as a promising therapeutic strategy for some cancers. In this study, we use liquid chromatography-mass spectrometry analysis to demonstrate differences in HS disaccharide content and structure across four patient-derived tumorsphere lines (GBM1, 5, 6, 43) and between two murine tumorsphere lines derived from murine GBM with enrichment of mesenchymal and proneural gene expression (mMES and mPN, respectively) markers. In GBM, the heterogeneous HS content and structure across patient-derived tumorsphere lines suggested diverse functions in the GBM tumor microenvironment. In GBM5 and mPN, elevated expression of sulfatase 2 (SULF2), an extracellular enzyme that alters ligand binding to HS, was associated with low trisulfated HS disaccharides, a substrate of SULF2. In contrast, other primary tumorsphere lines had elevated expression of the HS-modifying enzyme heparanase (HPSE). Using gene editing strategies to inhibit HPSE, a role for HPSE in promoting tumor cell adhesion and invasion was identified. These studies characterize the heterogeneity in HS glycosaminoglycan content and structure across GBM and reveal their role in tumor cell invasion.Implications: HS-interacting factors promote GBM invasion and are potential therapeutic targets. Mol Cancer Res; 15(11); 1623-33. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28778876      PMCID: PMC6059807          DOI: 10.1158/1541-7786.MCR-17-0352

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  62 in total

1.  Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation.

Authors:  A C Rapraeger; A Krufka; B B Olwin
Journal:  Science       Date:  1991-06-21       Impact factor: 47.728

2.  Specific degradation of subendothelial matrix proteoglycans by brain-metastatic melanoma and brain endothelial cell heparanases.

Authors:  D Marchetti
Journal:  J Cell Physiol       Date:  1997-09       Impact factor: 6.384

3.  Ultra-performance ion-pairing liquid chromatography with on-line electrospray ion trap mass spectrometry for heparin disaccharide analysis.

Authors:  Bo Yang; Amanda Weyers; Jong Youn Baik; Eric Sterner; Susan Sharfstein; Shaker A Mousa; Fuming Zhang; Jonathan S Dordick; Robert J Linhardt
Journal:  Anal Biochem       Date:  2011-04-15       Impact factor: 3.365

4.  Expression analysis of genes involved in brain tumor progression driven by retroviral insertional mutagenesis in mice.

Authors:  Fredrik K Johansson; Hanna Göransson; Bengt Westermark
Journal:  Oncogene       Date:  2005-06-02       Impact factor: 9.867

5.  Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma.

Authors:  Anurag Purushothaman; Ligong Chen; Yang Yang; Ralph D Sanderson
Journal:  J Biol Chem       Date:  2008-09-23       Impact factor: 5.157

Review 6.  Proteoglycans and their roles in brain cancer.

Authors:  Anna Wade; Aaron E Robinson; Jane R Engler; Claudia Petritsch; C David James; Joanna J Phillips
Journal:  FEBS J       Date:  2013-02-06       Impact factor: 5.542

7.  Comparative analyses of gene copy number and mRNA expression in glioblastoma multiforme tumors and xenografts.

Authors:  J Graeme Hodgson; Ru-Fang Yeh; Amrita Ray; Nicholas J Wang; Ivan Smirnov; Mamie Yu; Sujatmi Hariono; Joachim Silber; Heidi S Feiler; Joe W Gray; Paul T Spellman; Scott R Vandenberg; Mitchel S Berger; C David James
Journal:  Neuro Oncol       Date:  2009-01-12       Impact factor: 12.300

8.  Direct detection of HSulf-1 and HSulf-2 activities on extracellular heparan sulfate and their inhibition by PI-88.

Authors:  Md Motarab Hossain; Tomomi Hosono-Fukao; Renhong Tang; Noriko Sugaya; Toin H van Kuppevelt; Guido J Jenniskens; Koji Kimata; Steven D Rosen; Kenji Uchimura
Journal:  Glycobiology       Date:  2009-10-12       Impact factor: 4.313

9.  PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models.

Authors:  K Dredge; E Hammond; P Handley; T J Gonda; M T Smith; C Vincent; R Brandt; V Ferro; I Bytheway
Journal:  Br J Cancer       Date:  2011-02-01       Impact factor: 7.640

10.  Heparanase is a host enzyme required for herpes simplex virus-1 release from cells.

Authors:  Satvik R Hadigal; Alex M Agelidis; Ghadah A Karasneh; Thessicar E Antoine; Abraam M Yakoub; Vishnu C Ramani; Ali R Djalilian; Ralph D Sanderson; Deepak Shukla
Journal:  Nat Commun       Date:  2015-04-27       Impact factor: 14.919

View more
  14 in total

1.  MicroRNA-422a functions as a tumor suppressor in non-small cell lung cancer through SULF2-mediated TGF-β/SMAD signaling pathway.

Authors:  Wei-Qiang Li; Jian-Peng Zhang; Yan-Yu Wang; Xin-Zhen Li; Lin Sun
Journal:  Cell Cycle       Date:  2019-06-28       Impact factor: 4.534

2.  Heparan sulfate accumulation and perlecan/HSPG2 up-regulation in tumour tissue predict low relapse-free survival for patients with glioblastoma.

Authors:  Galina M Kazanskaya; Alexandra Y Tsidulko; Alexander M Volkov; Roman S Kiselev; Anastasia V Suhovskih; Vyacheslav V Kobozev; Alexei S Gaytan; Svetlana V Aidagulova; Alexei L Krivoshapkin; Elvira V Grigorieva
Journal:  Histochem Cell Biol       Date:  2018-01-10       Impact factor: 4.304

Review 3.  The multifaceted mechanisms of malignant glioblastoma progression and clinical implications.

Authors:  Rui Sun; Albert H Kim
Journal:  Cancer Metastasis Rev       Date:  2022-08-03       Impact factor: 9.237

4.  Endothelial cell-specific reduction of heparan sulfate suppresses glioma growth in mice.

Authors:  Takamasa Kinoshita; Hiroyuki Tomita; Hideshi Okada; Ayumi Niwa; Fuminori Hyodo; Tomohiro Kanayama; Mikiko Matsuo; Yuko Imaizumi; Takahiro Kuroda; Yuichiro Hatano; Masafumi Miyai; Yusuke Egashira; Yukiko Enomoto; Noriyuki Nakayama; Shigeyuki Sugie; Kazu Matsumoto; Yu Yamaguchi; Masayuki Matsuo; Hideaki Hara; Toru Iwama; Akira Hara
Journal:  Discov Oncol       Date:  2021-11-11

Review 5.  Glycomaterials to Investigate the Functional Role of Aberrant Glycosylation in Glioblastoma.

Authors:  Chaitanya Tondepu; Lohitash Karumbaiah
Journal:  Adv Healthc Mater       Date:  2021-12-29       Impact factor: 11.092

6.  Heparanase potentiates the invasion and migration of pancreatic cancer cells via epithelial‑to‑mesenchymal transition through the Wnt/β‑catenin pathway.

Authors:  Cheng Wang; Yajun Wei; Gang Wang; Yangming Zhou; Jingcheng Zhang; Kai Xu
Journal:  Oncol Rep       Date:  2020-06-10       Impact factor: 3.906

Review 7.  A Key Pathway to Cancer Resilience: The Role of Autophagy in Glioblastomas.

Authors:  Elisa Helena Farias Jandrey; Marcelle Bezerra; Lilian Tiemi Inoue; Frank B Furnari; Anamaria Aranha Camargo; Érico Tosoni Costa
Journal:  Front Oncol       Date:  2021-06-10       Impact factor: 6.244

8.  Heparan Sulfate Synthesized by Ext1 Regulates Receptor Tyrosine Kinase Signaling and Promotes Resistance to EGFR Inhibitors in GBM.

Authors:  Yuki Ohkawa; Anna Wade; Olle R Lindberg; Katharine Y Chen; Vy M Tran; Spencer J Brown; Anupam Kumar; Mausam Kalita; C David James; Joanna J Phillips
Journal:  Mol Cancer Res       Date:  2020-10-07       Impact factor: 6.333

9.  Heparan Sulfate Biosynthetic System Is Inhibited in Human Glioma Due to EXT1/2 and HS6ST1/2 Down-Regulation.

Authors:  Victor S Ushakov; Alexandra Y Tsidulko; Gabin de La Bourdonnaye; Galina M Kazanskaya; Alexander M Volkov; Roman S Kiselev; Vyacheslav V Kobozev; Diana V Kostromskaya; Alexey S Gaytan; Alexei L Krivoshapkin; Svetlana V Aidagulova; Elvira V Grigorieva
Journal:  Int J Mol Sci       Date:  2017-11-01       Impact factor: 5.923

10.  3D extracellular matrix microenvironment in bioengineered tissue models of primary pediatric and adult brain tumors.

Authors:  Disha Sood; Min Tang-Schomer; Dimitra Pouli; Craig Mizzoni; Nicole Raia; Albert Tai; Knarik Arkun; Julian Wu; Lauren D Black; Bjorn Scheffler; Irene Georgakoudi; Dennis A Steindler; David L Kaplan
Journal:  Nat Commun       Date:  2019-10-04       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.